Mimma Rizzo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1313920/publications.pdf

Version: 2024-02-01

65 papers	1,413 citations	393982 19 h-index	344852 36 g-index
68 all docs	68 docs citations	68 times ranked	2057 citing authors

#	Article	IF	Citations
1	Prospective phase II study of sunitinib rechallenge in metastatic renal cell carcinoma: The â€œretryâ€• study from the Italian Group of Onco-Nephrology (G.I.O.N.). Journal of Onco-Nephrology, 2022, 6, 107-114.	0.3	1
2	Statin use improves the efficacy of nivolumab in patients with advanced renal cell carcinoma. European Journal of Cancer, 2022, 172, 191-198.	1.3	8
3	Artificial Neural Networks as a Way to Predict Future Kidney Cancer Incidence in the United States. Clinical Genitourinary Cancer, 2021, 19, e84-e91.	0.9	23
4	A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC. Cancer Immunology, Immunotherapy, 2021, 70, 1667-1678.	2.0	27
5	The need for new algorithms of treatment sequencing in clear-cell metastatic renal cell carcinoma. Expert Review of Anticancer Therapy, 2021, 21, 401-412.	1.1	8
6	Treatment of muscle-invasive bladder cancer in patients without comorbidities and fit for surgery: Trimodality therapy vs radical cystectomy. Development of GRADE (Grades of Recommendation,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 5 and Clinical Oncology (AIRO). Critical Reviews in Oncology/Hematology, 2021, 159, 103235.	2.0	7
7	Individualizing renal cell carcinoma treatment through biomarkers discovery in the era of immune checkpoint inhibitors: where do we stand?. Current Opinion in Urology, 2021, 31, 236-241.	0.9	4
8	Lycopene minimizes skin toxicity and oxidative stress in patients treated with panitumumab-containing therapy for metastatic colorectal cancer. Journal of Functional Foods, 2021, 83, 104533.	1.6	8
9	Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study. Targeted Oncology, 2021, 16, 625-632.	1.7	6
10	Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro) Tj ETQq0 0 0 rgBT /Overlock 10	0.9	3
11	The heterogeneity of cancer endothelium: The relevance of angiogenesis and endothelial progenitor cells in cancer microenvironment. Microvascular Research, 2021, 138, 104189.	1.1	11
12	Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?. Diagnostics, 2021, 11, 138.	1.3	13
13	GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreak. Therapeutic Advances in Urology, 2021, 13, 175628722110543.	0.9	3
14	Playing the Devilâ€™s Advocate: Should We Give a Second Chance to mTOR Inhibition in Renal Clear Cell Carcinoma? â€“ ie Strategies to Revert Resistance to mTOR Inhibitors. Cancer Management and Research, 2021, Volume 13, 7623-7636.	0.9	6
15	Biological Therapeutic Advances for the Treatment of Advanced Urothelial Cancers. Biologics: Targets and Therapy, 2021, Volume 15, 441-450.	3.0	2
16	A Glimpse in the Future of Malignant Mesothelioma Treatment. Frontiers in Pharmacology, 2021, 12, 809337.	1.6	2
17	Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors. Cancers, 2020, 12, 84.	1.7	22
18	Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592096846.	1.4	14

#	Article	IF	Citations
19	The basics of onco-nephrology in the renal clinic. Journal of Nephrology, 2020, 33, 1143-1149.	0.9	3
20	Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions. OncoImmunology, 2020, 9, 1832348.	2.1	55
21	An evaluation of UGN-101, a sustained-release hydrogel polymer-based formulation containing mitomycin-C, for the treatment of upper urothelial carcinomas. Expert Opinion on Pharmacotherapy, 2020, 21, 2199-2204.	0.9	3
22	Treatment sequencing strategies in metastatic renal cell carcinoma: A critical interpretation of available data. Journal of Onco-Nephrology, 2020, 4, 153-164.	0.3	0
23	Safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma: a systematic review and meta-analysis. Expert Opinion on Drug Safety, 2020, 19, 1329-1338.	1.0	64
24	Clinical pharmacology of monoclonal antibodies targeting anti-PD-1 axis in urothelial cancers. Critical Reviews in Oncology/Hematology, 2019, 144, 102812.	2.0	7
25	Targeting angiogenesis in metastatic renal cell carcinoma. Expert Review of Anticancer Therapy, 2019, 19, 245-257.	1.1	12
26	Immune-based combination therapy for metastatic kidney cancer. Nature Reviews Nephrology, 2019, 15, 324-325.	4.1	3
27	Therapeutic options for first-line metastatic castration-resistant prostate cancer: Suggestions for clinical practise in the CHAARTED and LATITUDE era. Cancer Treatment Reviews, 2019, 74, 35-42.	3.4	30
28	Single nucleotide polymorphisms in angiogenesis-related genes and outcomes from antiangiogenic therapies in renal cell carcinoma: really a step towards personalized oncology, or not at all?. Annals of Translational Medicine, 2019, 7, S15-S15.	0.7	1
29	Aberrations of DNA Repair Pathways in Prostate Cancer: Future Implications for Clinical Practice?. Frontiers in Cell and Developmental Biology, 2018, 6, 71.	1.8	9
30	Metastatic castration-resistant prostate cancer in very elderly patients: challenges and solutions. Clinical Interventions in Aging, 2017, Volume 12, 19-28.	1.3	8
31	Optimisation and validation of a remote monitoring system (Onco-TreC) for home-based management of oral anticancer therapies: an Italian multicentre feasibility study. BMJ Open, 2017, 7, e014617.	0.8	25
32	Sunitinib in the treatment of renal cell carcinoma: an update on recent evidence. Therapeutic Advances in Urology, 2017, 9, 195-207.	0.9	47
33	Vinflunine for patients with urothelial carcinoma resistant to first-line platinum-containing chemotherapy. A pooled analysis of efficacy and safety results in the real-world setting. Annals of Oncology, 2016, 27, iv36.	0.6	0
34	Bone metastases affect prognosis but not effectiveness of third-line targeted therapies in patients with metastatic renal cell carcinoma. Canadian Urological Association Journal, 2015, 9, 263.	0.3	6
35	Surgical Resection Does Not Improve Survival in Patients with Renal Metastases to the Pancreas in the Era of Tyrosine Kinase Inhibitors. Annals of Surgical Oncology, 2015, 22, 2094-2100.	0.7	72
36	Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis. Annals of Oncology, 2015, 26, 2107-2113.	0.6	85

#	Article	IF	Citations
37	Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy. Targeted Oncology, 2015, 10, 517-522.	1.7	49
38	Everolimus as second-line therapy for metastatic renal cell carcinoma: a â€˜real-lifeâ€™ study. Future Oncology, 2015, 11, 219-224.	1.1	7
39	Sunitinib, Pazopanib or Sorafenib for the Treatment of Patients with Late Relapsing Metastatic Renal Cell Carcinoma. Journal of Urology, 2015, 193, 41-47.	0.2	58
40	Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: An up-to-date review and meta-analysis of clinical trials. International Journal of Cancer, 2015, 136, 1-10.	2.3	47
41	The Changes of Lipid Metabolism in Advanced Renal Cell Carcinoma Patients Treated with Everolimus: A New Pharmacodynamic Marker?. PLoS ONE, 2015, 10, e0120427.	1.1	9
42	Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib.. Canadian Urological Association Journal, 2014, 8, 121.	0.3	8
43	We need both randomized trials and real-world data: the example of everolimus as second-line therapy for mRCC. Future Oncology, 2014, 10, 1893-1896.	1.1	23
44	Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting. Future Oncology, 2014, 10, 1741-1750.	1.1	12
45	Retrospective observational study of sunitinib administered on schedule 2/1 in patients with metastatic renal cell carcinoma (mRCC): The rainbow study.. Journal of Clinical Oncology, 2014, 32, 471-471.	0.8	8
46	The ORCHIDEE Study: Gathering New Evidence on the use of Everolimus in Clinical Practice. Tumori, 2014, 100, e290-e292.	0.6	0
47	Differences in terms of progression-free survival (PFS) and overall survival (OS) in patients treated with first-line sorafenib, sunitinib, and pazopanib for late relapsing (>5 years) renal cell carcinoma.. Journal of Clinical Oncology, 2014, 32, 421-421.	0.8	0
48	Prognostic factors in patients with pancreatic metastases from renal cell carcinoma (PM-RCC): Room for thinking about the role of surgery?. Journal of Clinical Oncology, 2014, 32, e15563-e15563.	0.8	0
49	Calcitriol: a better option than vitamin D in denosumab-treated patients with kidney failure?. Expert Opinion on Biological Therapy, 2013, 13, 149-151.	1.4	16
50	Novel Agents, Combinations and Sequences for the Treatment of Advanced Renal Cell Carcinoma: When is the Revolution Coming?. Current Cancer Drug Targets, 2013, 13, 313-325.	0.8	8
51	Progression-free survival (PFS) and overall survival (OS) in patients receiving three targeted therapies (TTs) for metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2013, 31, 431-431.	0.8	1
52	Present and Future of Tyrosine Kinase Inhibitors in Renal Cell Carcinoma: Analysis of Hematologic Toxicity. Recent Patents on Anti-infective Drug Discovery, 2012, 7, 104-110.	0.5	20
53	Therapy innovation for the treatment of pancreatic neuroendocrine tumors. Expert Opinion on Therapeutic Targets, 2012, 16, S91-S102.	1.5	7
54	High CXCR4 Expression Correlates with Sunitinib Poor Response in Metastatic Renal Cancer. Current Cancer Drug Targets, 2012, 12, 693-702.	0.8	28

#	Article	IF	Citations
55	Prognostic Factors and Validation of Prognostic Nomograms in Patients (PTS) Treated with 3 Targeted Therapies (TTS) for Metastatic Renal Cell Carcinoma (MRCC): Results from an Italian Survey. Annals of Oncology, 2012, 23, ix276-ix277.	0.6	0
56	Neuroendocrine Tumors Diagnosed at the â€œAntonio Cardarelliâ€•Hospital (Naples, Campania, Italy) between 2006â€“2009: A Single-Institution Analysis. International Journal of Immunopathology and Pharmacology, 2011, 24, 251-256.	1.0	2
57	Phase II study of docetaxel reâ€treatment in docetaxelâ€pretreated castrationâ€resistant prostate cancer. BJU International, 2011, 107, 234-239.	1.3	82
58	Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases. BJU International, 2011, 108, E250-E257.	1.3	79
59	Pathological complete response induced by first-line chemotherapy with single agent docetaxel in a patient with advanced non small cell lung cancer. World Journal of Surgical Oncology, 2010, 8, 8.	0.8	3
60	29 FIRST LINE CHEMOTHERAPY WITH DOCETAXEL/GEMCITABINE/TRASTUZUMAB (GOIM 2611) IN PATIENT WITH ADVANCED BREAST CANCER HER-2 POS: A CASE REPORT OF EARLY AND PROLONGED RESPONSE. Cancer Treatment Reviews, 2010, 36, S103.	3.4	0
61	54 EPIDEMIOLOGY OF THE NEUROENDOCRINE TUMORS DIAGNOSED IN THE CARDARELLI HOSPITAL: A RETRO-SPECTIVE SINGLE-INSTITUTION ANALYSIS OF 299 CASES. Cancer Treatment Reviews, 2010, 36, S111.	3.4	0
62	55 THE HIGH INCIDENCE OF LUNG CANCER IN A GENERAL HOSPITAL: A RETROSPECTIVE SINGLE-INSTITUTION ANALYSIS IN 2009. Cancer Treatment Reviews, 2010, 36, S111.	3.4	0
63	Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Annals of Oncology, 2009, 20, 1535-1542.	0.6	180
64	Targeted Therapy in the Treatment of Metastatic Renal Cell Cancer. Oncology, 2009, 77, 122-131.	0.9	6
65	Phase II Study of Sorafenib in Patients With Sunitinib-Refractory Metastatic Renal Cell Cancer. Journal of Clinical Oncology, 2009, 27, 4469-4474.	0.8	131